522 related articles for article (PubMed ID: 31736936)
21. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.
Schettini J; Mukherjee P
Clin Dev Immunol; 2008; 2008():106321. PubMed ID: 19190769
[TBL] [Abstract][Full Text] [Related]
22. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
23. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells and autoimmunity.
Bayry J; Thirion M; Delignat S; Misra N; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
Autoimmun Rev; 2004 Mar; 3(3):183-7. PubMed ID: 15110229
[TBL] [Abstract][Full Text] [Related]
26. Human dendritic cell subsets for vaccination.
Dubsky P; Ueno H; Piqueras B; Connolly J; Banchereau J; Palucka AK
J Clin Immunol; 2005 Nov; 25(6):551-72. PubMed ID: 16380819
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell-based immunotherapy.
Berger TG; Schultz ES
Curr Top Microbiol Immunol; 2003; 276():163-97. PubMed ID: 12797448
[TBL] [Abstract][Full Text] [Related]
28. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
29. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity.
Tan JK; O'Neill HC
J Leukoc Biol; 2005 Aug; 78(2):319-24. PubMed ID: 15809288
[TBL] [Abstract][Full Text] [Related]
30. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
[TBL] [Abstract][Full Text] [Related]
33. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
Falcón-Beas C; Tittarelli A; Mora-Bau G; Tempio F; Pérez C; Hevia D; Behrens C; Flores I; Falcón-Beas F; Garrido P; Ascui G; Pereda C; González FE; Salazar-Onfray F; López MN
Immunobiology; 2019 Sep; 224(5):697-705. PubMed ID: 31221438
[TBL] [Abstract][Full Text] [Related]
34. mRNA therapeutics in cancer immunotherapy.
Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
[TBL] [Abstract][Full Text] [Related]
35. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.
Huang FP; Chen YX; To CK
Eur J Immunol; 2011 Jan; 41(1):18-25. PubMed ID: 21182072
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases.
Xiao BG; Huang YM; Link H
BioDrugs; 2003; 17(2):103-11. PubMed ID: 12641489
[TBL] [Abstract][Full Text] [Related]
37. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
[TBL] [Abstract][Full Text] [Related]
38. [Dendritic cells: orchestration of the immune response].
Martinon-Ego C; Berthier R
Ann Biol Clin (Paris); 2000; 58(5):541-56. PubMed ID: 11022098
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.
Anguille S; Lion E; Van den Bergh J; Van Acker HH; Willemen Y; Smits EL; Van Tendeloo VF; Berneman ZN
Hum Vaccin Immunother; 2013 Sep; 9(9):1956-61. PubMed ID: 23778748
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell preparation for immunotherapeutic interventions.
Simon T; Fonteneau JF; Grégoire M
Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
